These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 10358196)

  • 1. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
    Ekdahl KN; Nilsson B
    J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of coagulation factor XI by a casein kinase released by activated human platelets increases its susceptibility to activation by factor XIIa and thrombin.
    Ekdahl KN; Elgue G; Nilsson B
    Thromb Haemost; 1999 Oct; 82(4):1283-8. PubMed ID: 10544914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tick-over theory revisited: is C3 a contact-activated protein?
    Nilsson B; Nilsson Ekdahl K
    Immunobiology; 2012 Nov; 217(11):1106-10. PubMed ID: 22964236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
    Gyongyossy-Issa MI; McLeod E; Devine DV
    J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 9. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3.
    Luo S; Hartmann A; Dahse HM; Skerka C; Zipfel PF
    J Immunol; 2010 Aug; 185(4):2164-73. PubMed ID: 20644161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase. Inhibition of factor I-mediated cleavage of C3b.
    Ekdahl KN; Nilsson B
    J Immunol; 1995 Jun; 154(12):6502-10. PubMed ID: 7539023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface.
    Andersson J; Ekdahl KN; Lambris JD; Nilsson B
    Biomaterials; 2005 May; 26(13):1477-85. PubMed ID: 15522749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of chrysotile asbestos fibres with the complement system.
    Saint-Remy JM; Cole P
    Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An affinity for complement C3 as a possible reason for the potency of naturally occurring antibodies in mediating tissue homeostasis.
    Lutz HU; Fasler S; Stammler P
    Beitr Infusionsther; 1989; 24():193-9. PubMed ID: 2481539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: covariation with platelet activation and possible association with thrombosis.
    Ekdahl KN; Rönnblom L; Sturfelt G; Nilsson B
    Arthritis Rheum; 1997 Dec; 40(12):2178-86. PubMed ID: 9416855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human alternative complement pathway: biology and immunopathology of activation and regulation.
    Kazatchkine MD; Nydegger UE
    Prog Allergy; 1982; 30():193-234. PubMed ID: 7041132
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
    Moore FD; Austen KF; Fearon DT
    J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.